AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...
NEW YORK, May 21 (Reuters) - Abbott Laboratories Inc said on Wednesday its Humira medicine has maintained maximum effectiveness for a year or longer among roughly 29 percent of Crohn's disease ...
The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...
A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...
Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.’s (NYSE:ABBV) Humira, one of the world’s ...
SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of ...
Boehringer Ingelheim and GoodRx are launching a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer’s biosimilar to Humira (adalimumab), at a low cash price available ...
An advisory panel for the Food and Drug Administration concluded Tuesday that Thousand Oaks, Calif.-based Amgen’s version of AbbVie’s arthritis drug Humira should be approved, according to Reuters.
SpA-Related Diseases Share Gut Microbiota Dysbiosis Stool samples from patients with spondyloarthritis, acute anterior uveitis, and/or Crohn's disease showed similarly low levels of certain bacteria, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback